Litcius/Paper detail

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming‐Sound Tsao, Fred R. Hirsch

2021Nature Reviews Clinical Oncology1,560 citationsDOI

Topics & Concepts

MedicineBiomarkerConcordanceBiomarker discoveryOncologyCompanion diagnosticImmune checkpointClinical trialPD-L1CancerDiseaseInternal medicineImmunotherapyBioinformaticsBiologyProteomicsBiochemistryGeneCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCAR-T cell therapy research
PD-L1 as a biomarker of response to immune-checkpoint inhibitors | Litcius